Welcome to our dedicated page for Biohaven SEC filings (Ticker: BHVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biohaven鈥檚 SEC narrative is more than numbers鈥攊t鈥檚 the story of MoDE degraders, troriluzole milestones, and licensing deals that redefine neuroscience and immunology. But locating trial cost disclosures or spotting when executives sell shares in a 300-page report is hard.
Stock Titan makes Biohaven SEC filings explained simply. Our AI parses every annual report 10-K, quarterly earnings report 10-Q filing, and 8-K material events to highlight what moves valuation: cash runway, Phase-3 readouts, royalty streams, and partnership obligations. Need instant alerts on Biohaven Form 4 insider transactions real-time? We surface each executive stock transactions Form 4 with context so you know whether management is buying ahead of data or trimming exposure.
Use the platform to:
- Compare R&D spend trends across quarters for faster Biohaven earnings report filing analysis
- Monitor grant dates, option exercises, and Biohaven insider trading Form 4 transactions
- Quick-scan the Biohaven proxy statement executive compensation section without combing through exhibits
- Receive AI-powered plain-language digests鈥�understanding Biohaven SEC documents with AI takes minutes, not hours
Whether you鈥檙e tracking cash burn before FDA review or gauging sentiment through insider activity, our comprehensive, real-time feed keeps you ahead of the curve. Explore every disclosure with confidence鈥�Biohaven SEC filings, simplified.
Biohaven Ltd. reported a continued operating loss and a material financing transaction that altered its balance sheet. Total assets were $550.4 million versus $615.1 million at year-end, with $165.8 million in cash and cash equivalents and $239.2 million in marketable securities. The company recorded a net loss of $198.1 million for the quarter and $419.8 million for the six months, with basic and diluted loss per share of $1.94 and $4.11, respectively.
Biohaven completed a $250.0 million secured notes financing under a Note Purchase Agreement and elected fair-value accounting for those notes, which increased non-current notes payable to $257.1 million and raised total liabilities to $415.8 million. Research and development expense declined versus the prior-year periods, reducing operating expense and operating loss, but operating cash use remained substantial at $333.1 million for the six months. The company also reported significant contingent milestone and commercial payment obligations under license and acquisition agreements totaling up to $3.185 billion, which are not recognized as liabilities because the triggering events were not considered probable.
Biohaven Ltd. furnished a Current Report on Form 8-K to announce a press release reporting its financial results for the second quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and the cover page of the report is provided in Inline XBRL as Exhibit 104.
The filing states the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, and is not incorporated by reference in other filings except by specific reference. The registrant is organized in the British Virgin Islands, its common shares trade under BHVN on the New York Stock Exchange, and the report is signed by Chief Financial Officer Matthew Buten.
FAQ
What is the current stock price of Biohaven (BHVN)?
What is the market cap of Biohaven (BHVN)?
